These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 33391451)

  • 21. SOX11 expression as a MRD molecular marker for MCL in comparison with t(11;14) and IGH rearrangement.
    Szostakowska M; Szymczyk M; Badowska K; Tudek B; Fabisiewicz A
    Med Oncol; 2018 Mar; 35(4):49. PubMed ID: 29520657
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials.
    Lahuerta JJ; Paiva B; Vidriales MB; Cordón L; Cedena MT; Puig N; Martinez-Lopez J; Rosiñol L; Gutierrez NC; Martín-Ramos ML; Oriol A; Teruel AI; Echeveste MA; de Paz R; de Arriba F; Hernandez MT; Palomera L; Martinez R; Martin A; Alegre A; De la Rubia J; Orfao A; Mateos MV; Blade J; San-Miguel JF;
    J Clin Oncol; 2017 Sep; 35(25):2900-2910. PubMed ID: 28498784
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic implication of early minimal residual disease evaluation in patients with chronic myelomonocytic leukemia.
    Wang L; Chen R; Li L; Zhu L; Huang X; Ye X
    Am J Cancer Res; 2022; 12(5):2216-2225. PubMed ID: 35693086
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA.
    Cavo M; San-Miguel J; Usmani SZ; Weisel K; Dimopoulos MA; Avet-Loiseau H; Paiva B; Bahlis NJ; Plesner T; Hungria V; Moreau P; Mateos MV; Perrot A; Iida S; Facon T; Kumar S; van de Donk NWCJ; Sonneveld P; Spencer A; Krevvata M; Heuck C; Wang J; Ukropec J; Kobos R; Sun S; Qi M; Munshi N
    Blood; 2022 Feb; 139(6):835-844. PubMed ID: 34289038
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Blastoid variant of mantle cell lymphoma: late progression from classical mantle cell lymphoma and quantitation of minimal residual disease.
    Pott C; Schrader C; Brüggemann M; Ritgen M; Harder L; Raff T; Tiemann M; Dreger P; Kneba M
    Eur J Haematol; 2005 Apr; 74(4):353-8. PubMed ID: 15777349
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical Outcomes Based on Measurable Residual Disease Status in Patients with Core-Binding Factor Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis.
    Rotchanapanya W; Hokland P; Tunsing P; Owattanapanich W
    J Pers Med; 2020 Nov; 10(4):. PubMed ID: 33256157
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical significance of the lymphocyte-to-monocyte ratio in multiple myeloma patients with negative minimal residual disease: a single-center retrospective analysis.
    Suzuki K; Nishiwaki K; Nagao R; Katori M; Fukushima R; Hattori D; Masuoka H; Yano S
    Int J Hematol; 2021 Nov; 114(5):599-607. PubMed ID: 34339005
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Impact of minimal residual disease detection after treatment of multiple myeloma].
    Szendrei T; Plander M; Szabó Z; Kereskai L; Kajtár B; Papp G; Iványi JL
    Orv Hetil; 2019 Mar; 160(13):502-508. PubMed ID: 30907098
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Utility of Measurable Residual Disease (MRD) Assessment in Mantle Cell Lymphoma.
    Wu S; Blombery P; Westerman D; Tam CS
    Curr Treat Options Oncol; 2023 Aug; 24(8):929-947. PubMed ID: 37249800
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of Mantle Cell Lymphoma Contamination of Autologous Stem Cell Grafts on Outcome after High-Dose Chemotherapy.
    Roerden M; Wirths S; Sökler M; Bethge WA; Vogel W; Walz JS
    Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34071000
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group.
    Kovacs G; Robrecht S; Fink AM; Bahlo J; Cramer P; von Tresckow J; Maurer C; Langerbeins P; Fingerle-Rowson G; Ritgen M; Kneba M; Döhner H; Stilgenbauer S; Klapper W; Wendtner CM; Fischer K; Hallek M; Eichhorst B; Böttcher S
    J Clin Oncol; 2016 Nov; 34(31):3758-3765. PubMed ID: 27573660
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies.
    Cazzaniga G; De Lorenzo P; Alten J; Röttgers S; Hancock J; Saha V; Castor A; Madsen HO; Gandemer V; Cavé H; Leoni V; Köhler R; Ferrari GM; Bleckmann K; Pieters R; van der Velden V; Stary J; Zuna J; Escherich G; Stadt UZ; Aricò M; Conter V; Schrappe M; Valsecchi MG; Biondi A
    Haematologica; 2018 Jan; 103(1):107-115. PubMed ID: 29079599
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Minimal Residual Disease in Chronic Lymphocytic Leukemia in the Era of Novel Agents: A Review.
    Thompson M; Brander D; Nabhan C; Mato A
    JAMA Oncol; 2018 Mar; 4(3):394-400. PubMed ID: 28750119
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinical implication of minimal residual disease monitoring by 10-color flow cytometry in multiple myeloma].
    Yao WQ; Zhu MQ; Yan LZ; Jin S; Shang JJ; Yao Y; Yan S; Liu Y; Wu DP; Fu CC
    Zhonghua Xue Ye Xue Za Zhi; 2019 Sep; 40(9):720-725. PubMed ID: 31648471
    [No Abstract]   [Full Text] [Related]  

  • 35. Influence of pre-transplant minimal residual disease on prognosis after Allo-SCT for patients with acute lymphoblastic leukemia: systematic review and meta-analysis.
    Shen Z; Gu X; Mao W; Yin L; Yang L; Zhang Z; Liu K; Wang L; Huang Y
    BMC Cancer; 2018 Jul; 18(1):755. PubMed ID: 30037340
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma.
    Schulz H; Bohlius J; Skoetz N; Trelle S; Kober T; Reiser M; Dreyling M; Herold M; Schwarzer G; Hallek M; Engert A
    Cochrane Database Syst Rev; 2007 Oct; 2007(4):CD003805. PubMed ID: 17943799
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia.
    Ravandi F; Jorgensen J; Borthakur G; Jabbour E; Kadia T; Pierce S; Brandt M; Wang S; Konoplev S; Wang X; Huang X; Daver N; DiNardo C; Andreeff M; Konopleva M; Estrov Z; Garcia-Manero G; Cortes J; Kantarjian H
    Cancer; 2017 Feb; 123(3):426-435. PubMed ID: 27657543
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-World Experience of Measurable Residual Disease Response and Prognosis in Acute Myeloid Leukemia Treated with Venetoclax and Azacitidine.
    Ong SY; Tan Si Yun M; Abdul Halim NA; Christopher D; Jen WY; Gallardo C; Tan Hwee Yim A; Woon YK; Ng HJ; Ooi M; Wong GC
    Cancers (Basel); 2022 Jul; 14(15):. PubMed ID: 35892834
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Measurable Residual Disease Assessment and Allogeneic Transplantation as Consolidation Therapy in Adult Acute Lymphoblastic Leukemia in Colombia.
    Combariza JF; Arango M; Díaz L; Agudelo C; Hernandez S; Madera AM; León G; Avila V; Bautista L; Valdés J; Orduz R; Mejía F; Moreno L; Ramirez C
    Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e365-e372. PubMed ID: 33277225
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prospective evaluation of minimal residual disease monitoring to predict prognosis of adult patients with Ph-negative acute lymphoblastic leukemia.
    Nagafuji K; Miyamoto T; Eto T; Ogawa R; Okumura H; Takase K; Kawano N; Miyazaki Y; Fujisaki T; Wake A; Ohno Y; Kurokawa T; Kamimura T; Takamatsu Y; Yokota S; Akashi K
    Eur J Haematol; 2019 Sep; 103(3):164-171. PubMed ID: 31132205
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.